MedPath
HSA Approval

NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML

SIN15117P

NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML

NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML

November 9, 2016

BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS DRIP

Medical Information

L01XC17

xl 01 xc 17

Manufacturer Information

BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.

Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company

Active Ingredients

Nivolumab

10 mg/mL

Nivolumab

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML - HSA Approval | MedPath